Pfizer Corporation

Pfizer Vaccines, Lcc

Curadev Pharma Private Limited

David Cameron Pryde

Alan Daniel Brown

Lyn Howard Jones

Brian Robert Champion

Lee Richard Roberts

David Michael Wyatt

Robert McKenzie Owen

Anne Maria Kristina Kjerrstrom

David Paul Gervais

Donald Stuart Middleton

Alan Stobie

Andrew Simon Cook

Adam Gillmore

Stephen Challenger

Clare Christy

Mifune Takeuchi

Robert Mckenzie Owen

Peter M Jones

Kevin Neil Dack

Heather Lynn Davis

James Richard Merson

Christine Anne Louise Watson

Kiyoyuki Omoto

Monali Banerjee

Sandip Middya

Ritesh Shrivastava

Arjun Surya

Michael J McCluskie

Erin Kristen Parsons

David Robert Stead

Keshab Bhattacharya

Thien Duc Tran

Sourav Basu

Rajib Ghosh

Dharmendra Yadav

Nickolas Anastasiou

Jari Ilmari Finneman

Parag Ashok Kolhe

Paul Robert Mehelic

Jennifer Marie Thorn

David R Stead

David P Gervais

Clare Lees

Christine Ann Louise Watson

Peter Jones

Michael John Mccluskie

Christine Anne Watson

The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections. 

Small molecule modulators of human sting

The present invention relates to pyrazolopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I), and pharmaceutically acceptable salts thereof, wherein X, R, R, R, Rand Rare as defined in the description. The pyrazolopyridazine derivatives of the present invention modulate the activity of the GABAreceptor. They may useful in the treatment of a number of conditions, including pain and epilepsy. 

4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain

The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, R, Rand Rare as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAreceptor. They are useful in the treatment of a number of conditions, including pain.

Imidazopyridazine derivatives as modulators of the GABAA receptor activity

The present invention relates to the provision of novel immunogens comprising an antigenic IgE peptide preferably linked to an immunogenic carrier for the prevention, treatment or alleviation of IgE-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.

IgE CH3 peptide vaccine

The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.

Conjugates for the prevention or treatment of nicotine addiction

The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, R, Rand Rare as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAreceptor. They are useful in the treatment of a number of conditions, including pain.

Chemical compounds

The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer. 

Pharmaceuticals

This invention relates to purine derivatives, to processes for their preparation, to compositions containing them and to their use. The present invention provides compounds of formula (I)  More particularly, the present invention relates to the use of purine derivatives in the treatment of a variety of viral infections and immune or inflammatory disorders, including those in which the modulation, in particular agonism, of Toll-Like Receptors (TLRs) is implicated. Accordingly, the compounds of the invention are useful in the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infections, inflammatory diseases such as asthma and arthritis, and cancer.

Purine derivatives

The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein Ris optionally substituted Calkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, Calkoxy, &#x2014;NRRor &#x2014;NRSOR; X is the linkage &#x2014;(CH)&#x2014; or &#x2014;(CH)&#x2014;O&#x2014; (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by Calkoxy; hydroxy; hydroxy(Calkyl); Ccycloalkyl; carbocyclyl; heterocyclyl; or by Calkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two Rgroups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.

N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase

The invention relates to compounds of formula (I) for treating for example sexual dysfunction, wherein R is optionally substituted C alkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, hydrogen, C alkoxy, &mdash;NR R or &mdash;NR SO R ; X is the linkage &mdash;(CH ) &mdash; or &mdash;(CH ) &mdash;O&mdash; (wherein Y is attached to the oxygen); wherein one or more hydrogen atoms in linkage X may be replaced independently by C alkoxy; hydroxy; hydroxy(C alkyl); C cycloalkyl; carbocyclyl; heterocyclyl; or by C alkyl optionally substituted by one or more fluoro or phenyl groups; n is 3, 4, 5, 6 or 7; and q is 2, 3, 4, 5 or 6; and Y is phenyl or pyridyl, each of which may be substituted; or two R groups on adjacent carbon atoms together with the interconnecting carbon atoms may form a fused optionally substituted 5- or 6-membered carbocyclic or heterocyclyic ring.

Growing community of inventors

Sandwich, United Kingdom

David Cameron Pryde